Specialized Neurology Focus Britannia Pharmaceuticals specializes exclusively in neurology, particularly Parkinson's disease treatments, which positions it as a key partner for healthcare providers and clinics focusing on neurological disorders.

Growing Revenue Stream With an estimated revenue between $10 million and $25 million, Britannia presents an attractive opportunity for pharmaceutical suppliers and service providers interested in the UK's neurological care market.

Industry Group Affiliation As part of the STADA Arzneimittel AG group, Britannia benefits from strong industry backing, indicating stability and potential for collaborative ventures in pharmaceutical development and distribution.

Potential Customer Base The company's focus on innovative treatments for serious and chronic conditions suggests opportunities to engage with hospital systems, neurologists, and specialty clinics actively treating Parkinson's and related disorders.

Employee and Market Size With a staff of 51 to 200 employees and operating within a niche market, Britannia offers a manageable yet significant client profile for tailored sales approaches, emphasizing high-value, specialized medical solutions.